SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that the company will present new preclinical data highlighting the potential of its small molecule APOL1 inhibitor as a treatment for APOL1 kidney disease. The data will be presented during a poster session at the American Society of Nephrology’s Kidney Week 2023, from November 2-5, 2023, in Philadelphia.
“APOL1 kidney disease is a life threatening, genetically driven condition that is estimated to impact close to one million people of West African descent in the U.S. alone,” said Harold Bernstein, M.D., Ph.D., president, research and development, and chief medical officer of Maze. “Our latest findings that we will present at ASN are further demonstration of our program’s potential to treat a significant sub-population suffering from chronic kidney disease. It also underscores the power of the Maze Compass platform to elucidate important insights into the genetic drivers of disease.”
Poster Title: Small molecule inhibition of APOL1 reverses albuminuria in a chronic mouse model of APOL1-mediated kidney disease
Poster Board #: SA-PO788
Session Title: Genetic Diseases: Glomerulopathies - II [PO1202-3]
Session Date, Time: November 4, 2023, from 10:00 a.m. to 12:00 p.m. ET
About Maze Therapeutics
Maze Therapeutics is a biopharmaceutical company harnessing the power of human genetics to transform the lives of patients. The Company is committed to developing breakthrough precision medicines for common diseases with large unmet medical needs. Maze has developed Maze Compass™, a proprietary, purpose-built platform to leverage genetic variation and integrate the critical step of variant functionalization into each stage of therapeutic development. Utilizing Maze Compass, the Company’s strategy is to develop its therapies independently, in collaboration with major pharmaceutical companies, and through company formation. For more information, please visit mazetx.com, or follow us on LinkedIn and X (formerly Twitter).
